SEC Comment Letter 0000000000-23-013686 to NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258) (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258)
Date: Dec. 15, 2023 · CIK: 0001936258 · Accession: 0000000000-23-013686
AI Filing Summary & Sentiment
File numbers found in text: 333-275932
Letter
United States securities and exchange commission logo December 15, 2023 Michael Davidson Chief Executive Officer NewAmsterdam Pharma Co N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands Re:NewAmsterdam Pharma Co N.V. Registration Statement on Form F-3 Filed December 7, 2023 File No. 333-275932 Dear Michael Davidson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brianna M. Bloodgood
Show Raw Text
United States securities and exchange commission logo
December 15, 2023
Michael Davidson
Chief Executive Officer
NewAmsterdam Pharma Co N.V.
Gooimeer 2-35
1411 DC Naarden
The Netherlands
Re:NewAmsterdam Pharma Co N.V.
Registration Statement on Form F-3
Filed December 7, 2023
File No. 333-275932
Dear Michael Davidson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brianna M. Bloodgood